Leadership & Pay ·
Imunon, Inc.'s Compensation Committee approved compensatory programs allowing certain executive officers to elect to…
IMNNImunon, Inc.
Imunon, Inc.'s Compensation Committee approved compensatory programs allowing certain executive officers to elect to receive a percentage of their base salary in common stock. President and CEO Stacy Lindborg may convert up to 50% of his salary into shares, receiving additional equity equal to 12% (amended to 35% for August 14/17 issuances) or 17.5% of the net stock payment value on subsequent pay dates through September 25, 2026. Executive Chairman Michael Tardugno may convert up to 100% of his salary, receiving additional shares equal to 20%, 40%, or 20% of the net stock payment amount depending on the issuance date between July 31 and September 25, 2026. Chief Medical Officer Douglas Faller may convert up to 40% of his salary, with additional shares valued at 12% (amended to 15%) of the net stock payment from July 31 through September 25, 2026. Imunon, Inc. operates in the biotechnology industry, focusing on cancer immunotherapy.